Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines

  • Authors:
    • Naruji Kugimiya
    • Eijiro Harada
    • Yuki Suehiro
    • Atsushi Suga
    • Yoshihiro Takemoto
    • Kimikazu Hamano
  • View Affiliations

  • Published online on: March 21, 2019     https://doi.org/10.3892/ol.2019.10181
  • Pages: 5267-5274
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to prospectively clarify the prognostic effect of the expression of several genes that are known to modulate 5‑fluorouracil effects in 63 patients who underwent curative resection for stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines between 2008 and 2012. Thymidine phosphorylase (TP) expression in primary tumours was significantly lower in the recurrence group compared with the no‑recurrence group (P=0.03), whereas, expression levels of genes that encoded thymidylate synthase, dihydropyrimidine dehydrogenase, folylpolyglutamate synthase, γ‑glutamyl hydrolase and dihydrofolate reductase were not statistically different in tumours from the recurrence and no‑recurrence groups. In the multivariate analysis using stepwise Cox proportional hazards regression, the following factors were significantly associated with shorter relapse‑free survival following adjuvant chemotherapy with oral fluoropyrimidines: Venous invasion [present; hazard ratio (HR)=6.51; 95% confidence interval (CI): 1.55‑27.4; P=0.01), Tumour‑Node‑Metastasis stage (3b; HR=6.18; 95% CI: 1.36‑28.2; P=0.02) and TP expression (low; HR=9.61; 95% CI: 1.81‑51.0; P=0.04). Patients with two or more risk characteristics had significantly shorter 5‑year relapse‑free survival compared with patients with one or no risk characteristics (55.8 vs. 91.8%; log‑rank P=0.0006). We concluded that low TP expression is an independent predictive factor for poor prognosis in colorectal cancer. Therefore, determining TP expression may help to improve recurrence risk stratification in patients with stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines.

References

1 

Twelves C, Wong A, Nowacki MP, Abt M, Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI

2 

Shimada Y, Hamaguchi T, Mizusawa J, Saito N, Kanemitsu Y, Takiguchi N, Ohue M, Kato T, Takii Y, Sato T, et al: Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: Final results of JCOG0205. Eur J Cancer. 50:2231–2240. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Leichman CG, Lenz H-J, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 15:3223–3229. 1997. View Article : Google Scholar : PubMed/NCBI

4 

Lenz H-J, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP, et al: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin Cancer Res. 4:1243–1250. 1998.PubMed/NCBI

5 

Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E and Ardalan B: Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: Implications for chemotherapeutic options and survival. Cancer J Sci Am. 5:34–40. 1999.PubMed/NCBI

6 

Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ, et al: Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer. 82:560–567. 2000. View Article : Google Scholar : PubMed/NCBI

7 

Fujii R, Seshimo A and Kameoka S: Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol. 8:72–78. 2003. View Article : Google Scholar : PubMed/NCBI

8 

Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G and Barone C: Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology. 70:366–377. 2006. View Article : Google Scholar : PubMed/NCBI

9 

Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol. 12:2640–2647. 1994. View Article : Google Scholar : PubMed/NCBI

10 

Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Hatano K, Kitayama J, Tsuruo T and Muto T: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol. 7:193–198. 2000. View Article : Google Scholar : PubMed/NCBI

11 

Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P and Blomgren H: Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol. 20:1721–1728. 2002. View Article : Google Scholar : PubMed/NCBI

12 

Donada M, Bonin S, Nardon E, De Pellegrin A, Decorti G and Stanta G: Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability. J Cancer Res Clin Oncol. 137:201–210. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N, Schneider M, Thyss A, Demard F and Milano G: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol. 13:1663–1670. 1995. View Article : Google Scholar : PubMed/NCBI

14 

Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 6:1322–1327. 2000.PubMed/NCBI

15 

Lassmann S, Hennig M, Rosenberg R, Nährig J, Schreglmann J, Krause F, Poignee-Heger M, Nekarda H, Höfler H and Werner M: Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis. 21:238–247. 2006. View Article : Google Scholar : PubMed/NCBI

16 

Tokunaga Y, Sasaki H and Saito T: Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. Surgery. 141:346–353. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Ochiai T, Umeki M, Miyake H, Iida T, Okumura M, Ohno K, Sakamoto M, Miyoshi N, Takahashi M, Tsumura H, et al: Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. Oncol Rep. 32:887–892. 2014. View Article : Google Scholar : PubMed/NCBI

18 

Mori T, Ohue M, Takii Y, Hashizume T, Kato T, Kotake K, Sato T and Tango T: Factors predicting the response to oral fluoropyrimidine drugs: A phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study). Oncol Rep. 29:437–444. 2013. View Article : Google Scholar : PubMed/NCBI

19 

Koda K, Miyauchi H, Kosugi C, Kaiho T, Takiguchi N, Kobayashi S, Maruyama T and Matsubara H; Boso Clinical Oncology Group, : Tumor 5-FU-related mRNA expression and efficacy of oral fluoropyrimidines in adjuvant chemotherapy of colorectal cancer. Anticancer Res. 36:5325–5331. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L and Danenberg PV: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res. 4:2371–2376. 1998.PubMed/NCBI

21 

Tokunaga Y, Hosogi H, Hoppou T, Nakagami M, Tokuka A and Ohsumi K: Prognostic value of thymidine phosphorylase/platelet-derived endothelial cell growth factor in advanced colorectal cancer after surgery: Evaluation with a new monoclonal antibody. Surgery. 131:541–547. 2002. View Article : Google Scholar : PubMed/NCBI

22 

Saito S, Tsuno N, Nagawa H, Sunami E, Zhengxi J, Osada T, Kitayama J, Shibata Y, Tsuruo T and Muto T: Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. Cancer. 88:42–49. 2000. View Article : Google Scholar : PubMed/NCBI

23 

Odin E, Wettergren Y, Nilsson S, Willén R, Carlsson G, Spears CP, Larsson L and Gustavsson B: Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res. 9:6012–6019. 2003.PubMed/NCBI

24 

Satta T, Isobe K, Yamauchi M, Nakashima I, Akiyama S, Itou K, Watanabe T and Takagi H: Establishment of drug resistance in human gastric and colon carcinoma xenograft lines. Jpn J Cancer Res. 82:593–598. 1991. View Article : Google Scholar : PubMed/NCBI

25 

Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S and Liotta LA: Laser capture microdissection: Molecular analysis of tissue. Science. 278:1481–1483, 1483. 1997. View Article : Google Scholar : PubMed/NCBI

26 

Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, et al: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 4:135–142. 2000. View Article : Google Scholar : PubMed/NCBI

27 

Bronckaers A, Gago F, Balzarini J and Liekens S: The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev. 29:903–953. 2009. View Article : Google Scholar : PubMed/NCBI

28 

Che J, Pan L, Yang X, Liu Z, Huang L, Wen C, Lin A and Liu H: Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5-fluorouracil-based chemotherapy: A meta-analysis. Mol Clin Oncol. 7:943–952. 2017.PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kugimiya, N., Harada, E., Suehiro, Y., Suga, A., Takemoto, Y., & Hamano, K. (2019). Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines. Oncology Letters, 17, 5267-5274. https://doi.org/10.3892/ol.2019.10181
MLA
Kugimiya, N., Harada, E., Suehiro, Y., Suga, A., Takemoto, Y., Hamano, K."Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines". Oncology Letters 17.6 (2019): 5267-5274.
Chicago
Kugimiya, N., Harada, E., Suehiro, Y., Suga, A., Takemoto, Y., Hamano, K."Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines". Oncology Letters 17, no. 6 (2019): 5267-5274. https://doi.org/10.3892/ol.2019.10181